News Gene Test May Predict Which MS Patients Will Respond to Interferon-beta Therapy Gene Test May Predict Which MS Patients Will Respond to Interferon-beta Therapy by Patricia Silva, PhD | November 9, 2016 Share this article: Share article via email Copy article link In multiple sclerosis (MS) patients who do not respond toĀ interferon-beta treatment, autoimmunity may depend on processes that differ from patients helped by this treatmentā a finding that could lead both to better therapies and tests that predict a patient’s likely response. The study, āAn interferon-Ī²-resistant and NLRP3 inflammasomeāindependent subtype of EAE with neuronal damage,ā was published in the journal Nature Neuroscience. Interferon-betaĀ isĀ a first line of therapy to prevent MS flares, but it does not work in sizable groups of patients. Up to now, clinicians and scientists had no way of knowing if a patient would be helped by the treatment or not, and for those unfortunate not to respond, finding that outĀ is long, costly, and detrimental. Researchers at Duke University in North Carolina turned to a mouse model of an MS-like disease, called experimental autoimmune encephalomyelitis (EAE), to learn more about the different responses. In an earlier study, the research team ā led by Mari Shinohara, an associate professor of immunology at Duke ā found that interferon-beta treatment helps to prevent MS relapses by blocking a complex of proteins known as the NLRP3 inflammasome. This structure seemed to trigger processes that allow the immune system to attack the brain. But the study also revealed that some mice got sick without NLRP3 inflammasome involvement, indicating that different disease routes could lead to autoimmune activation and damage. Interestingly, these mice also did not react to interferon-beta treatment. The researchers decided to explore exactly how the mice differed. In their new study, they reported that two receptors, called CXCR2 and LTBR, were crucial for promotingĀ disease in interferon-resistant mice. Blocking these two receptors succeeded in doing what the interferon had failed to do ā protecting the mice from disease relapses. āThe study shows a really clear molecular mechanism that may explain why some people do not respond to interferon-beta treatment,ā Shinohara, the study’s senior author, said in a news release. ButĀ mice and humans do differ, so to explore if the receptors were involved also in human MS, the team used genetic data from another MS study. Comparing geneĀ activity in patients who responded to interferon treatment with those who did not revealedĀ that the genes for these two receptors were more active inĀ non-responders. Higher gene activity canĀ translate to more of the receptors being produced. Researchers now hope to explore whether the gene activity levels of a patient can tell beforehand whether that personĀ is likely to be helped by interferon treatment. āNow these patients have to go through all the pain, inconvenience and cost of interferon-beta treatment, only to be told that it doesnāt work for them,ā said Shinohara. āSo itās a big problem, and it would be really nice if we could tell upfront which treatment works.ā Dr. Xiaoxia Li with the Cleveland Clinic, who was not involved in the study, highlighted the value of the findings in opening new diagnostic or treatment options. āThis new model gives us opportunities to explore a different disease mechanism that has been elusive to the field thus far,ā Li said. āI believe it will have a large impact on both the basic and translational research on multiple sclerosis.ā Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags EAE, interferon-beta, NLRP3 inflammasome, relapses
April 26, 2024 News by Margarida Maia, PhD Employment, income drop steadily over 2 decades after onset of MS
April 26, 2024 News by Marisa Wexler, MS Machine learning model predicts CIS to MS conversion risk: Study
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression